Trevi Therapeutics (NASDAQ:TRVI) Lifted to “Strong-Buy” at EF Hutton Acquisition Co. I

Trevi Therapeutics (NASDAQ:TRVI) was upgraded by EF Hutton Acquisition Co. I to a “strong-buy” rating in a note issued to investors on Monday, Zacks.com reports.

TRVI has been the subject of several other research reports. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 8th. Rodman & Renshaw assumed coverage on shares of Trevi Therapeutics in a report on Thursday, June 13th. They set a “buy” rating and a $7.00 price target for the company.

Trevi Therapeutics Trading Down 4.0 %

Shares of NASDAQ:TRVI opened at $2.85 on Monday. The company has a fifty day simple moving average of $2.80 and a 200 day simple moving average of $2.78. The firm has a market cap of $206.88 million, a PE ratio of -8.38 and a beta of 1.00. Trevi Therapeutics has a 12-month low of $0.97 and a 12-month high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter in the previous year, the company posted ($0.07) EPS. As a group, equities research analysts forecast that Trevi Therapeutics will post -0.46 EPS for the current fiscal year.

Insider Buying and Selling

In other Trevi Therapeutics news, insider Thomas Sciascia sold 53,368 shares of the company’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $2.55, for a total value of $136,088.40. Following the completion of the sale, the insider now directly owns 214,433 shares of the company’s stock, valued at approximately $546,804.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 72,128 shares of company stock valued at $187,865 over the last 90 days. 24.37% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. lifted its holdings in Trevi Therapeutics by 7.3% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock valued at $9,891,000 after acquiring an additional 500,000 shares during the last quarter. Opaleye Management Inc. raised its holdings in Trevi Therapeutics by 48.6% during the 4th quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after buying an additional 829,100 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in Trevi Therapeutics during the 1st quarter worth about $208,000. Vanguard Group Inc. raised its holdings in Trevi Therapeutics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after buying an additional 60,249 shares during the period. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Trevi Therapeutics during the 1st quarter worth about $47,000. 95.76% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.